American Heart Month — Basic Scientists Seek to Uncover the Fundamentals of Heart Disease Risk Factors

Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding avenues that could advance drugs that regulate blood sugar, alleviate high blood pressure and improve how heart disease is treated.

Helmsley Charitable Trust Awards $3 Million Grant to Research Epithelial Healing in Crohn’s disease

he Helmsley Charitable Trust has awarded a grant of $3,035,566 to support groundbreaking research on Crohn’s disease, to be led by a collaborative team of leading researchers across three institutions. Louis J. Cohen, MD, Assistant Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai; Parakkal Deepak, MD, Associate Professor of Medicine (Gastroenterology), Washington University School of Medicine; and Andres J. Yarur, MD, Associate Professor of Medicine (Gastroenterology), Cedars-Sinai Medical Center, will serve as co-investigators.

Popular diabetes and weight-loss drug associated with lower opioid overdose risk

Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic—which has devastated families and communities nationally. Semaglutide was found to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).

Combining Two Diabetes Drugs Helps Promote Weight Loss and Blood Sugar Control

New research finds a combination of drugs improves weight loss, glucose control and insulin resistance better than either drug alone. Using two diabetes medications together, such as a semaglutide like Ozempic or Rybelsus, with a second, newer class of drug, may offer a noninvasive solution to help people with Type 2 diabetes lose weight and manage their condition without the need for bariatric surgery.

New study shows popular diabetes and weight-loss drugs associated with lower risk for tobacco-use disorder

A new study by researchers at the Case Western Reserve School of Medicine reveals popular diabetes and weight-loss drugs are linked to a lower risk for tobacco-use disorder (TUD) in smokers with type 2 diabetes, compared with seven other anti-diabetes medications.

New Cedars-Sinai Study Investigates Shifting Trends in GLP-1RA Prescription

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.

Retrospective Study Based on Electronic Health Records Finds Popular Diabetes and Weight-Loss Drugs Associated with Reduction in Incidence and Recurrence of Alcohol-Use Disorder by at Least Half

A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.

Obesity drugs and mental health: UTSW expert says GLP-1s may exacerbate problems for some patients

New weight-loss drugs have helped people with their diabetes, obesity, even high blood pressure. But how they affect our mental health is a much more complicated issue, says Dr. Carrie McAdams, a psychiatrist and eating disorders expert at UT Southwestern…

Should heart patients consider taking weight loss medications?

Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.

Researchers at UC Irvine issue a warning that GLP-1RA’s may be dangerous for children

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RA’s) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.

MEDIA ADVISORY: Cedars-Sinai Experts Available to Discuss Safety, Benefits of Using Medications to Lose Weight

The science is unclear on exactly why an increasingly popular new class of federally approved diabetes and obesity medications work, but they do know that they are effective at helping people lose weight.

Patients Taking Popular Medications for Diabetes and Weight Loss Should Stop Before Elective Surgery, ASA Suggests

With the growing popularity of medications like Ozempic® (semaglutide), Trulicity® (dulaglutide), and other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes and weight loss, the American Society of Anesthesiologists (ASA) suggests withholding the medication before elective surgery to reduce the risk of complications associated with anesthesia in adults and children.